title: [Meloxicam: the golden mean of nonsteroidal anti-inflammatory drugs].
abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are most commonly used to treat acute and chronic pain in locomotor system (LMS) diseases. However, their administration may be accompanied by the development of dangerous complications as organic and functional disorders of the cardiovascular system (CVS) and gastrointestinal tract (GIT). Physicians have currently a wide range of NSAIDs at their disposal; but none of the representatives of this group can be considered the best. Thus, highly selective cyclooxygenase-2 inhibitors (Coxibs) are substantially safer for GIT; however, their use is clearly associated with the increased risk of severe cardiovascular events. Nonselective NSAIDs, such as naproxen or ketoprofen, are safer for CVS, but more frequently cause significant GIT organic and functional disorders. Moderately selective NSAIDs, such as meloxicam (movalis), conceivably could be the most acceptable choice for treating the majority of patients in this situation. This drug has been long and extensively used in global clinical practice and has gained the confidence of physicians and patients. The major benefits of meloxicam are its proven efficacy, convenient treatment regimen, relatively low risk of complications as organic and functional disorders of the GIT and CVD and good compatibility with low-dose aspirin.
authors.forename: A E
authors.initials: AE
authors.lastname: Karateev
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000145:classification / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control*; D059350:Chronic Pain / Q000188:drug therapy* / Q000209:etiology; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D000077239:Meloxicam; D009140:Musculoskeletal Diseases / Q000145:classification / Q000150:complications*; D059352:Musculoskeletal Pain / Q000188:drug therapy* / Q000209:etiology; D063868:Patient Outcome Assessment; D020379:Risk Adjustment; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam